** = Publikationen gelistet in SCI/SSCI/Pubmed
** Suppan, C; Graf, R; Jahn, S; Zhou, Q; Klocker, EV; Bartsch, R; Terbuch, A; Kashofer, K; Regitnig, P; Lindenmann, J; Posch, F; Gerritsmann, H; Jost, PJ; Heitzer, E; Dandachi, N; Balic, M
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer. 2022; 126(3):456-463
Doi: 10.1038/s41416-021-01601-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Klocker, EV; Balic, M; Steger, G
Molecular profiling leading to personalized treatment in breast cancer
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-021-00792-4
Web of Science
FullText
FullText_MUG
** Adelsmayr, G; Haidmayer, A; Spreizer, C; Janisch, M; Quehenberger, F; Klocker, E; Graninger, W; Fuchsjäger, M; Hermann, J
The value of MRI compared to conventional radiography in analysing morphologic changes in the spine in axial spondyloarthritis.
Insights Imaging. 2021; 12(1): 183
Doi: 10.1186/s13244-021-01127-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Dandachi, N; Posch, F; Graf, R; Suppan, C; Klocker, EV; Müller, HD; Lindenmann, J; Terbuch, A; Heitzer, E; Balic, M
Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR+ breast cancer patients undergoing CDK4/6 treatment.
Mol Oncol. 2021; 15(9):2390-2400
Doi: 10.1002/1878-0261.12870
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Suppan, C; Posch, F; Mueller, HD; Mischitz, N; Steiner, D; Klocker, EV; Setaffy, L; Bargfrieder, U; Hammer, R; Hauser, H; Jost, PJ; Dandachi, N; Lax, S; Balic, M
Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.
Cancers (Basel). 2021; 13(10):
Doi: 10.3390/cancers13102492
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Suppan, C; Steiner, D; Klocker, EV; Posch, F; Henzinger, E; Muller, HD; Stoger, H; Dandachi, N; Balic, M
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
BREAST CARE. 2021;
Doi: 10.1159/000513766
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Suppan, C; Zhou, Q; Jahn, S; Graf, R; Klocker, EV; Terbuch, A; Kashofer, K; Posch, F; Gerritsmann, H; Dandachi, N; Heitzer, E; Balic, M
Comparison of liquid biopsy and tissue based detection of PIK3CAmutations in HR positive metastatic breast cancer patients
CANCER RES. 2021; 81(4):
[Poster]
Web of Science
** Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M; Gerger, A; Pichler, M
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.
Cancer Med. 2020; 9(15):5473-5479
Doi: 10.1002/cam4.3233
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Klocker, EV; Barth, DA; Riedl, JM; Prinz, F; Szkandera, J; Schlick, K; Kornprat, P; Lackner, K; Lindenmann, J; Stöger, H; Stotz, M; Gerger, A; Pichler, M
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.
Cancers (Basel). 2020; 12(5):
Doi: 10.3390/cancers12051154
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stotz, M; Barth, DA; Riedl, JM; Asamer, E; Klocker, EV; Kornprat, P; Hutterer, GC; Prinz, F; Lackner, K; Stöger, H; Gerger, A; Pichler, M
The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer.
Cancers (Basel). 2020; 12(7):
Doi: 10.3390/cancers12071798
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Klocker, EV; Suppan, C
Biomarkers in Her2-Positive Disease.
BREAST CARE. 2020; 15(6): 586-593.
Doi: 10.1159/000512283
Web of Science
FullText
FullText_MUG
** Suppan, C; Steiner, D; Klocker, VE; Posch, F; Henzinger, EC; Stoeger, H; Dandachi, N; Balic, M
Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.
J CLIN ONCOL. 2020; 38(15):
[Onlinepräsentation]
Web of Science
FullText
** Lembeck, AL; Posch, F; Klocker, EV; Szkandera, J; Schlick, K; Stojakovic, T; Kornprat, P; Lackner, C; Gerger, A; Stoeger, H; Stotz, M; Pichler, M
Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.
Clin Chem Lab Med. 2019; 57(5):740-744
Doi: 10.1515/cclm-2018-0016
Web of Science
PubMed
FullText
FullText_MUG